US FDA Grants Expanded Approval Of IlluminOss Photodynamic Bone Stabilization System For Use In Femur And Tibia Fractures As Supplemental Fixation

IlluminOss Medical, a medical device company focused on minimally invasive orthopedic fracture repair, announced an expanded US Food and Drug Administration (US FDA 510k) clearance for its Photodynamic Bone Stabilization System. The new clearance allows IlluminOss to be used in femur and tibia fractures as supplemental fixation to US FDA-cleared fracture fixation systems."Femur and tibia fractures can be challenging in aging patients where osteoporotic bone often lacks the strength required for reliable fixation with traditional hardware systems," said Robert Rabiner, chief technology officer of IlluminOss. "This new clearance allows the surgical community to use the IlluminOss intramedullary implant as a supplement to these systems and help prevent construct failures by dramatically improving the holding power of screws and other hardware." "Many lower limb fractures in the elderly, especially close to the knee joint, can be very difficult to achieve reliable stabilization due to poor bone quality," said Mike Mogul, chairman of IlluminOss. "As a minimally invasive means of supplementing hardware systems, IlluminOss provides substantial improvement in screw purchase and can optimize surgical outcomes. Surgeons can now securely affix their hardware anywhere along the length of the IlluminOss implant." The IlluminOss System is a minimally invasive approach for fracture repair and stabilization through a patient-conforming intramedullary implant. The system utilizes a light-curable liquid monomer, contained within an expandable balloon, to create a patient-conforming, rigid implant within the bone canal. The IlluminOss technology has been in clinical use in Europe since 2010, and in the US since 2018, with over 4,000 procedures to date

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!